empty
 
 
rs
Search
Podrška
Trenutno otvaranje računa
Trgovačka platforma
Depozit/Povlačenje
Search
Za početnike Za trgovce Za partnere Idi na pauzu About InstaSpot
rs
#AZN Nazad na listu instrumenata #BIIB

Menjač valuta

BeiGene Ltd.
189.69 USD
26 Nov 2024 20:41
Promena cene (% chg)
$0.39
(0.21%)
Cena prethodnog zatvaranja
Cena prethodnog zatvaranja

Cena zatvaranja prethodnog dana.
$189.02
Otvaranje
Otvaranje

Cena na otvaranju.
$191.2
Dnevni maksimum
Dnevni maksimum

Najviša cena tokom poslednjeg dana trgovine.
$190.36
Dnevni minimum
Dnevni minimum

Najniža cena tokom poslednjeg dana trgovine
$185.22
Maksimum u 52 nedelje
Maksimum u 52 nedelje

Opseg najviših cena u poslednje 52 nedelje
$190.36
Minimum u 52 nedelje
Minimum u 52 nedelje

Opseg najnižinih cena u poslednje 52 nedelje
$183.79
Preuzmi arhivu
Buy
189.69
Sell
189.69
Otvori grafikon za pregled na celom ekranu
Buy
189.69
Sell
189.69
Preuzmi arhivu
Otvori grafikon za pregled na celom ekranu

BeiGene Ltd. About company

BeiGene Ltd. is a China-based biotechnology company founded in 2010 in Beijing. Nowadays, the company operates on an international scale with its branches established in the US, Australia, and Europe.

The company focuses on the development of drugs for cancer treatment. Since 2019, BeiGene Ltd. has been in partnership with Amgen Inc. and since, 2021 – with Novartis.

The market capitalization of BeiGene Ltd. is worth $17.7 billion. The company yielded a profit of $1.176 billion last year. In the first half of 2022, it earned $341.57 million. On the flip side, its net losses measured $1.413 billion in 2021 and $571.45 million in the first half of 2022.

BeiGene Ltd.’s stock and what influences its market quotes

BeiGene Ltd.’s stock has traded on the Nasdaq exchange under a BGNE ticker since 2016. Shortly after the listing, the shares traded at $24 apiece.

For the time being, the stock is trading in the range of $138 to $145. The stock has traded between the borders of $121.11 and $389.34 over the last 12 months.

The company does not pay dividends. All funds raised through investments are allocated for research and development.

What factors should investors keep an eye on when trading this asset:

  • BeiGene’s business belongs to a rapidly-developing sector. So, the company should have its finger on the pulse of science not to lag behind its competitors.
  • The major risk is that the company is sensitive to regulatory acts.
  • Washington slaps sanctions on Chinese companies now and then. In this context, they might be delisted from American exchanges.
  • The company ranks high. Hence, its stock is attractive to investors.

Ne možete da razgovarate sada?
Postavite pitanje kroz ćaskanje.